CPT® Code 80356

1. Indications

The laboratory test coded as CPT® 80356 is indicated for the detection of the heroin metabolite 6-monoacetylmorphine (6-MAM) in patients who may have used heroin. This test is particularly relevant in the context of substance abuse evaluations, toxicology screenings, and monitoring of individuals in treatment programs for opioid dependence. It may also be utilized in legal or forensic settings where the presence of heroin metabolites needs to be established.

• Substance Abuse Evaluation This test is used to assess individuals suspected of heroin use as part of a comprehensive substance abuse evaluation.
• Toxicology Screening It is employed in toxicology screenings to identify recent heroin consumption, especially in emergency or clinical settings.
• Monitoring Treatment Programs The test can be used to monitor patients in rehabilitation or treatment programs for opioid dependence, ensuring compliance and assessing relapse.
• Legal and Forensic Testing It may be required in legal cases to provide evidence of heroin use in individuals involved in criminal investigations or custody disputes.

2. Procedure

The procedure for testing for the heroin metabolite 6-MAM involves several key steps to ensure accurate results. First, a blood sample is obtained through a process known as venipuncture, which is a separately reportable procedure. This involves inserting a needle into a vein to collect the necessary blood specimen. For urine testing, a specimen can be collected either through random voiding or catheterization, depending on the clinical scenario and the need for a controlled collection method. Once the specimens are collected, the testing methods differ based on the type of sample. For serum and plasma, quantitative liquid chromatography-tandem mass spectrometry is utilized, which allows for precise measurement of the metabolite levels. In contrast, urine samples are initially screened using a qualitative enzyme immunoassay, which provides a preliminary indication of the presence of 6-MAM. If the initial screening yields a positive result, further confirmation is conducted using quantitative high-performance chromatography-tandem mass spectrometry, ensuring the reliability and accuracy of the test results.

• Step 1: Blood Sample Collection A blood sample is obtained through venipuncture, which is a separate reportable procedure.
• Step 2: Urine Sample Collection Urine specimens are collected either by random void or catheterization, depending on the clinical requirements.
• Step 3: Testing Serum and Plasma Serum and plasma samples are analyzed using quantitative liquid chromatography-tandem mass spectrometry for accurate measurement.
• Step 4: Urine Screening Urine samples are screened with a qualitative enzyme immunoassay to detect the presence of 6-MAM.
• Step 5: Confirmation of Positive Results Positive urine screening results are confirmed through quantitative high-performance chromatography-tandem mass spectrometry.

3. Post-Procedure

After the procedure, the collected specimens are processed and analyzed in the laboratory. For urine tests, results are typically available within a short timeframe, allowing for timely clinical decision-making. In cases where a positive result is obtained from the urine screening, further confirmation through quantitative methods is essential to ensure accuracy. Patients may not require specific post-procedure care, but it is important for healthcare providers to communicate the results to the patients and discuss any necessary follow-up actions or treatment options based on the findings. Additionally, documentation of the test results and the procedures followed is crucial for compliance and record-keeping purposes.